The rising prevalence of metabolic disorders in the United States and around the world is alarming, especially those conditions that affect the liver—central to metabolic health.
One in three American adults has metabolic syndrome, a group of conditions that includes coronary heart disease, diabetes and stroke. Liver disease is equally prevalent. It’s estimated that 20-30% of adults in the U.S. have metabolic-dysfunction associated steatotic liver disease (MASLD) and 5-10% have the more severe form called metabolic-dysfunction associated steatohepatitis or MASH, which can lead to scarring (cirrhosis), liver cancer and organ failure.
Worldwide, the estimated prevalence of MASLD is 38%.
Our goal is to identify and interpret the underlying causes and drivers of metabolic and liver diseases, a continuum of research that includes basic intracellular signaling, metabolic translational research, human physiological studies and clinical trials.
Literally millions of people endure or face lives of chronic poor health, diminished well being and eventual death from metabolic diseases. Current therapeutic options are limited, ineffective or don’t exist at all. We want to change that.
Director’s Statement
“With the ongoing obesity epidemic and the ever-increasing consumption of calorie-dense foods, metabolic and liver diseases have become one of the nation’s top public health problems, affecting nearly one-third of Americans.
The mission of our center is to coordinate, facilitate and conduct cutting edge research on type 2 diabetes, insulin resistance, metabolic dysfunction associated steatotic liver disease (MASLD), MASLD-related liver fibrosis and cancer, as well as inborn errors of metabolism.
Our center will also emphasize the clinical translation of our basic research with the goal of finding new cures and preventive measures.”
Jun 30, 2025
Jun 10, 2025
Jan 28, 2025
Jan 17, 2025
Jan 9, 2025
Dec 6, 2024